Mobile

An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-003888-71

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

It is the aim of this study to show superiority of Zoledronic acid in prevention of bone loss, administered in combination with Letrozole as extended adjuvant therapy of postmenopausal women with primary hormone receptor positive breast cancer compared to Letrozole alone. Primary efficacy variable: Treatment difference in change in BMD measured by DXA in lumbar spine (L1-L4) at 36 months as compared to baseline.

Critère d'inclusion

  • prevention of tumortherapy-induced bone loss

Liens